Route links
- PMN Business
Author of the article:
Content of the article
The U.S. Centers for Disease Control and Prevention (CDC) on Friday released recommendations from its group of independent experts on a smallpox vaccine that limit its use to people who work closely with viruses such as smallpox. of the monkey.
The Jynneos vaccine, manufactured by Bavarian Nordic, will be available to certain health care workers and laboratory staff at a time when monkeypox infections have spread to Europe, the United States and beyond.
The vaccine was approved in the United States in 2019 to prevent smallpox and monkeypox in high-risk adults 18 years of age and older.
Announcement 2
This ad has not yet been uploaded, but your article continues below.
Content of the article
CDC officials earlier this week said they were in the process of releasing some doses of the Jynneos vaccine to people in contact with known monkeypox patients.
Officials said there were more than 100 million doses of an old smallpox vaccine called ACAM2000, made by Emergent BioSolutions, which has significant side effects.
Smallpox is a mild viral infection that is endemic in parts of Africa, but the recent outbreak in countries where the virus is not used to spread has raised concerns.
To date, there are about 300 confirmed or suspected cases in about 20 countries where the virus was not previously circulating. The World Health Organization has called for swift action by countries to curb the spread of smallpox.
Announcement 3
This ad has not yet been uploaded, but your article continues below.
Content of the article
The CDC said its experts’ recommendations are aimed at clinical laboratory staff who perform diagnostic tests for orthopoxviruses such as smallpox and monkeypox, laboratory people who conduct virus research, and health care workers who administer ACAM2000 vaccine or treat patients infected with orthopoxvirus.
The publication of the CDC Immunization Practice Advisory Committee vote, which took place in November last year, formalizes the recommendations.
Both ACAM2000 and Jynneos are available for the prevention of orthopoxvirus infections among people at risk, the CDC said Friday. (Report by Manas Mishra and Amruta Khandekar in Bangalore; edited by Krishna Chandra Eluri and Shailesh Kuber)
Share this article on your social network
Announcements
This ad has not yet been uploaded, but your article continues below.
Main news from Financial Post
Sign up for the latest Daily News from Financial Post, a division of Postmedia Network Inc.
By clicking the sign up button, you agree to receive the previous Postmedia Network Inc. newsletter. You can unsubscribe at any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
Thanks for signing up!
A welcome email is on its way. If you don’t see it, check your junk folder.
The next issue of Financial Post Top Stories will soon be in your inbox.
We encountered a problem registering you. Please try again
Comments
Postmedia is committed to maintaining a lively but civil discussion forum and encouraging all readers to share their views on our articles. Comments can take up to an hour to moderate before appearing on the site. We urge you to keep your comments relevant and respectful. We’ve enabled email notifications – you will now receive an email if you receive a response to your comment, there is an update to a comment thread you are following, or if a user is still commenting. Visit our Community Guidelines for more information and details on how to adjust your email settings.